NCT00278876View on ClinicalTrials.gov

Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

March 31, 2011

Conditions
SarcomaGastrointestinal Stromal Tumors
Interventions
DRUG

Imatinib mesylate (Glivec)

Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks

Trial Locations (4)

Unknown

National Cancer Center, Goyang

Asan Medical Center, Seoul

Seoul National University Hospital, Seoul

Seoul Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER